Age: 72.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: COVID-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Type 2 diabetes mellitus and Drug allergy (Allergy to unknown drug). Concomitant products included METFORMIN, DULAGLUTIDE (TRULICITY), LOSARTAN, GLIMEPIRIDE and ATORVASTATIN for an unknown indication.   On 30-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Feb-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-Oct-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Apr-2022, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 27-May-2022 to 31-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) had resolved.            Patient also received unspecified concomitant medication. Patient reported that patient experienced simple rebound on 06-Jun-2022, about a week after stopping treatment medication Paxlovid. Device Date reported as 06Jun2022. This spontaneous case reported by a patient, concerns a 72-year-old male patient with medical history of Type 2 diabetes mellitus and Drug allergy, Concomitant products included METFORMIN, DULAGLUTIDE, LOSARTAN, GLIMEPIRIDE and ATORVASTATIN, received dose of mRNA-1273 Vaccine on 30-Jan, 20-Feb, 20-Oct-2021 and on 22-Apr-2022 who experienced the unexpected non serious AESI event of Covid 19 infection about 1 1/2 months after receiving the a dose of mRNA-1273 vaccine in the covid 19 vaccination series. It was reported that the patient was treated with Paxlovid starting on 27-May to 31-May-2022 for covid-19 treatment. Details of the onset date, lab results and symptoms of this initial Covid 19 infection and its outcome was not reported.  On 6-June-2022, the patient again experienced COVID-19. Treatment for the event was not provided. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per medical judgement.   This case was linked to MOD-2022-584184 (Patient Link).; Sender's Comments: This spontaneous case reported by a patient, concerns a 72-year-old male patient with medical history of Type 2 diabetes mellitus and Drug allergy, Concomitant products included METFORMIN, DULAGLUTIDE, LOSARTAN, GLIMEPIRIDE and ATORVASTATIN, received dose of mRNA-1273 Vaccine on 30-Jan, 20-Feb, 20-Oct-2021 and on 22-Apr-2022 who experienced the unexpected non serious AESI event of Covid 19 infection about 1 1/2 months after receiving the a dose of mRNA-1273 vaccine in the covid 19 vaccination series. It was reported that the patient was treated with Paxlovid starting on 27-May to 31-May-2022 for covid-19 treatment. Details of the onset date, lab results and symptoms of this initial Covid 19 infection and its outcome was not reported.  On 6-June-2022, the patient again experienced COVID-19. Treatment for the event was not provided. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per medical judgement.